"The one-room antibody that we selected as the result of the laboratory research conducted in recent months by the MAD (Monoclonal Antibody Discovery) Lab, was produced by Menarini Biotech of Pomezia and we are now really one step away from the start of clinical trials, expected for early January ".
Andrea Paolini, general director of the Toscana Life Sciences Foundation, a pole of scientific excellence, explains this to ANSA.
"Phase 1, which will verify the safety of the therapy - he specifies - will be carried out on healthy people and conducted by the Spallanzani Institute in Rome and by the Clinical Research Center in Verona".